Takeda's livtencity™ (maribavir) now available for certain individuals ages 12 years and older with post-transplant cytomegalovirus (cmv) infection/disease in the united states

Cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced the united states commercial availability of livtencity™ (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (cmv) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.1
TAK Ratings Summary
TAK Quant Ranking